Abstract 6586: Updates to UALCAN, a comprehensive cancer proteogenomic data analysis platform for discovery research (2024)

Skip Nav Destination

Article navigation

Volume 83, Issue 7_Supplement

1 April 2023

  • Abstract

Poster Presentations - Proffered Abstracts| April 04 2023

Darshan Shimoga Chandrashekar;

Darshan Shimoga Chandrashekar

1University of Alabama at Birmingham, Birmingham, AL;

Search for other works by this author on:

This Site

Sooryanarayana Varambally;

Sooryanarayana Varambally

1University of Alabama at Birmingham, Birmingham, AL;

Search for other works by this author on:

This Site

Santhosh Kumar Karthikeyan;

Santhosh Kumar Karthikeyan

1University of Alabama at Birmingham, Birmingham, AL;

Search for other works by this author on:

This Site

Praveen Kumar Korla;

Praveen Kumar Korla

1University of Alabama at Birmingham, Birmingham, AL;

Search for other works by this author on:

This Site

Henalben Patel;

Henalben Patel

1University of Alabama at Birmingham, Birmingham, AL;

Search for other works by this author on:

This Site

Mohammad Athar;

Mohammad Athar

1University of Alabama at Birmingham, Birmingham, AL;

Search for other works by this author on:

This Site

Upender Manne;

Upender Manne

1University of Alabama at Birmingham, Birmingham, AL;

Search for other works by this author on:

This Site

George J. Netto;

George J. Netto

1University of Alabama at Birmingham, Birmingham, AL;

Search for other works by this author on:

This Site

Ahmedur Rahman Shovon;

Ahmedur Rahman Shovon

1University of Alabama at Birmingham, Birmingham, AL;

Search for other works by this author on:

This Site

Sidharth Kumar;

Sidharth Kumar

1University of Alabama at Birmingham, Birmingham, AL;

Search for other works by this author on:

This Site

Zhaohui S. Qin;

Zhaohui S. Qin

2Emory University, Atlanta, GA;

Search for other works by this author on:

This Site

Chad J. Crieghton

Chad J. Crieghton

3Baylor College of Medicine, Houston, TX.

Search for other works by this author on:

This Site

Author & Article Information

Online ISSN: 1538-7445

Print ISSN: 0008-5472

©2023 American Association for Cancer Research

2023

American Association for Cancer Research

Cancer Res (2023) 83 (7_Supplement): 6586.

  • Split-Screen
  • Views Icon Views
    • Article contents
    • Figures & tables
    • Video
    • Audio
    • Supplementary Data
    • Peer Review
  • Tools Icon Tools
  • Search Site
  • Article Versions Icon Versions
    • Version of Record April 4 2023

Citation

Darshan Shimoga Chandrashekar, Sooryanarayana Varambally, Santhosh Kumar Karthikeyan, Praveen Kumar Korla, Henalben Patel, Mohammad Athar, Upender Manne, George J. Netto, Ahmedur Rahman Shovon, Sidharth Kumar, Zhaohui S. Qin, Chad J. Crieghton; Abstract 6586: Updates to UALCAN, a comprehensive cancer proteogenomic data analysis platform for discovery research. Cancer Res 1 April 2023; 83 (7_Supplement): 6586. https://doi.org/10.1158/1538-7445.AM2023-6586

Download citation file:

  • Ris (Zotero)
  • Reference Manager
  • EasyBib
  • Bookends
  • Mendeley
  • Papers
  • EndNote
  • RefWorks
  • BibTex
toolbar search

Search Dropdown Menu

Advanced Search

Abstract

Background: Recent advances in high throughput technologies and initiation of multiple consortium driven projects have led to generation of high volume of molecular data related to thousands of cancer patients. These high throughput data are extremely useful for novel biomarker identification, therapeutic target identification in tumor subclasses and allows numerous hypothesis driven cancer research projects. However, the sheer volume of data and diverse data formats presents tremendous challenge for researchers with no programming experience to access and analyze comprehensively. These factors prompted us to develop UALCAN (University of ALabama CANcer portal, Yes! You All Can) for comprehensive cancer data analysis in a user-friendly manner. UALCAN enables cancer researchers/clinicians in tumor subgroup based gene expression, protein expression and survival analyses. UALCAN is extremely popular among cancer researchers round the world with well over a “MILLION” site visits and cited over 3400 times in research articles. UALCAN integrates The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC), as well as gene expression data from Children Brain Tumor Tissue Consortium (CBTTC). Users can also analyze non-coding RNA (miRNA and lncRNA) expression data from The Cancer Genome Atlas (TCGA) and the epigenetic data though the promoter DNA methylation analysis form the TCGA data.

Results: UALCAN now enables user to study expression profile of ~10000 proteins in 14 CPTAC cancers and expression pattern and survival impact of 20,500 protein-coding, ~17,000 lncRNA and 1800 miRNA in 33 TCGA cancers. It also facilitates analysis of gene expression pattern in pediatric brain cancer. User-friendly graphical user interface of UALCAN facilitates a) analyzing protein/non-coding RNA expression in tumor subgroups based on race, stage, age and molecular types; b) identifying top differentially expressed lncRNA/miRNA in specific cancer subtype; c) listing potential gene targets of non-coding RNA; d) performing pan-cancer analysis and e) determining impact of gene expression on patient’s overall survival.

Conclusions: UALCAN is freely available at http://ualcan.path.uab.edu (Google: UALCAN) This dynamic data portal provides constant updates that empower cancer researchers in studying gene and protein level expression and identifying tumor subgroup specific non-coding RNA biomarkers. UALCAN serves a one-stop platform for access, study, analyze and leverage large cancer datasets.

Citation Format: Darshan Shimoga Chandrashekar, Sooryanarayana Varambally, Santhosh Kumar Karthikeyan, Praveen Kumar Korla, Henalben Patel, Mohammad Athar, Upender Manne, George J. Netto, Ahmedur Rahman Shovon, Sidharth Kumar, Zhaohui S. Qin, Chad J. Crieghton. Updates to UALCAN, a comprehensive cancer proteogenomic data analysis platform for discovery research [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6586.

©2023 American Association for Cancer Research

2023

American Association for Cancer Research

Advertisem*nt

323 Views

View Metrics

×

Citing articles via

Google Scholar

Email alerts

Article Activity Alert

eTOC Alert

Close Modal

Abstract 6586: Updates to UALCAN, a comprehensive cancer proteogenomic data analysis platform for discovery research (2024)

FAQs

What is the full form of Ualcan? ›

The University of ALabama at Birmingham CANcer data analysis Portal. UALCAN is a comprehensive, user-friendly, and interactive web resource for analyzing cancer OMICS data.

What kind of information will be made available by the cancer Genome Atlas TCGA )? ›

Over the next dozen years, TCGA generated over 2.5 petabytes of genomic, epigenomic, transcriptomic, and proteomic data. The data, which has already led to improvements in our ability to diagnose, treat, and prevent cancer, will remain publicly available for anyone in the research community to use.

What is the cancer database for research? ›

The NCDB is a clinical oncology database sourced from hospital registry data collected in more than 1,500 Commission on Cancer-accredited facilities. These data are used to analyze and track patients with malignant neoplastic diseases, their treatments, and outcomes.

What sort of role do you think TCGA information will play in cancer diagnosis and cancer treatment in the future? ›

What sort of role do you think TCGA information will play in cancer diagnosis and cancer treatment in the future? The common genetic changes associated with each cancer type and subtype are expected to lead to more effective strategies for cancer detection and custom - designed treatment.

What is the Oncomine database? ›

Here, we present ONCOMINE, a cancer microarray database and web-based data-mining platform aimed at facilitating discovery from genome-wide expression analyses.

What is the full form of MDS EB1? ›

MDS = myelodysplastic syndrome; MDS-EB1, MDS-EB2 = MDS with excess blasts, subtype 1 or 2.

What is the largest cancer database? ›

The NCDB, begun in 1989, now contains approximately 40 million records from hospital cancer registries across the United States.

What is the methylation database for cancer? ›

MethMarkerDB is the first cancer DNA methylation biomarker database constructed on WGBS data. This unique resource offers precise genomic location information for biomarkers, encompassing both biomarker genes and DMRs.

What kind of information can genomic data provide? ›

Genomic data includes information like the sequence of molecules in an organism's genes. It also includes the function of each gene, the regulatory elements that control gene expression, and the interactions between different genes and proteins.

Where can I get cancer data? ›

Incidence data are provided by:
  • The Centers for Disease Control and Prevention National Program of Cancer Registries (NPCR)
  • The National Cancer Institute Surveillance, Epidemiology and End Results (SEER) program.

How is cancer data used? ›

These data are used to understand cancer rates and trends, support cancer research, measure progress in cancer control and prevention efforts, focus action on eliminating disparities, and improve cancer outcomes for all.

Who does the best cancer research? ›

Harvard University in Cambridge, Massachusetts, has the world's leading Share of cancer research, and more than one-fifth of its total Nature Index output is in this area.

Why is a genome database useful for understanding cancer? ›

By analysing patient genomes base-by-base, WGS allows the detection of pathogenic mutations in all regions of the genome – including protein-coding genes and non-coding DNA. When combined with transcriptome analysis, WGS can also give researchers a comprehensive view of cancer as it progresses in response to therapy.

What is the role of bioinformatics in cancer research? ›

Bioinformatics also helps in identifying common biomarkers and differentially expressed genes in different cancer types which further improves the process of cancer diagnosis.

What does a cancer researcher do for cancer? ›

Clinical cancer researchers conduct clinical trials, study a particular patient or group of patients, including their behaviors, or use materials from humans, such as blood or tissue samples, to learn about disease, how the healthy body works, or how it responds to treatment.

What is the full form of Ussocom? ›

The U.S. Special Operations Command (USSOCOM) oversees the special operations capabilities of the various military branches, coordinates their training, strategy, interoperability and operations.

What is the full form of HPSP? ›

Health Professions Scholarship Program (HPSP)

What is the full form of UPnP? ›

Universal Plug and Play (UPnP) is a standard that lets network devices automatically find, communicate with and control each other. It is used by routers, computers, printers, game consoles and IoT devices. It uses industry standard protocols such as IP, HTTP and Extensible Markup Language.

What is the full form of Rcog in medical terms? ›

The Royal College of Obstetricians and Gynaecologists (RCOG) is the professional body that oversees the medical education, training and examination of obstetricians and gynaecologists in the UK.

Top Articles
Latest Posts
Article information

Author: Msgr. Benton Quitzon

Last Updated:

Views: 6551

Rating: 4.2 / 5 (63 voted)

Reviews: 86% of readers found this page helpful

Author information

Name: Msgr. Benton Quitzon

Birthday: 2001-08-13

Address: 96487 Kris Cliff, Teresiafurt, WI 95201

Phone: +9418513585781

Job: Senior Designer

Hobby: Calligraphy, Rowing, Vacation, Geocaching, Web surfing, Electronics, Electronics

Introduction: My name is Msgr. Benton Quitzon, I am a comfortable, charming, thankful, happy, adventurous, handsome, precious person who loves writing and wants to share my knowledge and understanding with you.